These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18172780)

  • 1. B-cell depletion in Wegener's granulomatosis.
    Hinze CH; Colbert RA
    Clin Rev Allergy Immunol; 2008 Jun; 34(3):372-9. PubMed ID: 18172780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.
    Keogh KA; Ytterberg SR; Fervenza FC; Carlson KA; Schroeder DR; Specks U
    Am J Respir Crit Care Med; 2006 Jan; 173(2):180-7. PubMed ID: 16224107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report.
    Ooka S; Maeda A; Ito H; Omata M; Yamada H; Ozaki S
    Mod Rheumatol; 2009; 19(1):80-3. PubMed ID: 18806927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal & ocular targets for therapy in Wegener's granulomatosis.
    Joshi L; Hamour S; Salama AD; Pusey CD; Lightman S; Taylor SR
    Inflamm Allergy Drug Targets; 2009 Mar; 8(1):70-9. PubMed ID: 19275695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
    Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
    Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
    Specks U; Fervenza FC; McDonald TJ; Hogan MC
    Arthritis Rheum; 2001 Dec; 44(12):2836-40. PubMed ID: 11762944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.
    Aries PM; Hellmich B; Voswinkel J; Both M; Nölle B; Holl-Ulrich K; Lamprecht P; Gross WL
    Ann Rheum Dis; 2006 Jul; 65(7):853-8. PubMed ID: 16269425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.
    Aouba A; Pagnoux C; Bienvenu B; Mahr A; Guillevin L
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):65-73. PubMed ID: 18270860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood.
    Ferraro AJ; Smith SW; Neil D; Savage CO
    Nephrol Dial Transplant; 2008 Sep; 23(9):3030-2. PubMed ID: 18586761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wegener's granulomatosis effectively treated with rituximab: a case study.
    Kowalewska B; Szechiński J; Roszkowska E
    Pol Arch Med Wewn; 2008 Jun; 118(6):381-5. PubMed ID: 18619196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.
    Brihaye B; Aouba A; Pagnoux C; Cohen P; Lacassin F; Guillevin L
    Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S23-7. PubMed ID: 17428359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palisading neutrophilic granulomatous dermatitis in a Japanese patient with Wegener's granulomatosis.
    Kawakami T; Obara W; Soma Y; Mizoguchi M
    J Dermatol; 2005 Jun; 32(6):487-92. PubMed ID: 16043926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.
    Omdal R; Wildhagen K; Hansen T; Gunnarsson R; Kristoffersen G
    Scand J Rheumatol; 2005; 34(3):229-32. PubMed ID: 16134730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for refractory Wegener's granulomatosis.
    Antoniu SA
    Expert Opin Investig Drugs; 2006 Sep; 15(9):1115-7. PubMed ID: 16916277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Wegener's granulomatosis with anti-MPO c-ANCA revealed by uveitis].
    Mbéthé GL; Diéval C; Lafitte A; Roger-Schmeltz J; Longy-Boursier M; Mercié P
    Rev Med Interne; 2010 Oct; 31(10):e11-3. PubMed ID: 20605280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.
    Miloslavsky EM; Lu N; Unizony S; Choi HK; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Fervenza F; Monach PA; Specks U; Stone JH
    Arthritis Rheumatol; 2016 Dec; 68(12):2945-2952. PubMed ID: 27428559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Lee RW; D'Cruz DP
    Drugs; 2008; 68(6):747-70. PubMed ID: 18416584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide.
    Henes JC; Fritz J; Koch S; Klein R; Horger M; Risler T; Kanz L; Koetter I
    Clin Rheumatol; 2007 Oct; 26(10):1711-5. PubMed ID: 17502992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs.
    Selamet U; Kovaliv YB; Savage CO; Harper L
    Expert Opin Investig Drugs; 2007 May; 16(5):689-703. PubMed ID: 17461741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.